PDL BioPharma to Present at the 12th Annual BIO CEO & Investor Conference on February 8, 2010
INCLINE VILLAGE, Nev., Feb 02, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 12th Annual BIO CEO & Investor Conference in New York City on Monday, February 8, 2010 at 2:00 p.m. Eastern Time.
To access the live and subsequently archived webcast of the conference call, go to the company's website at http://www.pdl.com and click "Investors." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. A replay will be available at www.pdl.com starting approximately three hours after completion of the webcast.
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
SOURCE PDL BioPharma, Inc.